Nifuroxazide-d4
(Synonyms: 硝呋齐特 d4) 目录号 : GC48839
An internal standard for the quantification of nifuroxazide
Cas No.:1188487-83-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nifuroxazide-d4 is intended for use as an internal standard for the quantification of nifuroxazide by GC- or LC-MS. Nifuroxazide is a nitrofuran antibiotic.1 It is active against strains of the enteropathogenic bacteria C. jejuni, Salmonella, Y. enterocolitica, Shigella, and E. coli.1 It inhibits quorum sensing and virulence factor production in P. aeruginosa.2 Nifuroxazide inhibits STAT3 activity in a reporter assay (IC50 = ~3 µM) and decreases viability of U266 and INA-6 myeloma cells, which have constitutive STAT3 phosphorylation, with EC50 values of approximately 4.5 µM for both.3 It also decreases viability, migration, and invasion of, and induces apoptosis in, MCF-7, 4T1, and MDA-MB-231 breast cancer cells.4 Nifuroxazide (50 mg/kg per day) reduces tumor growth and prevents pulmonary metastasis in a 4T1 murine mammary carcinoma model. It also reduces diarrhea, weight loss, and colon inflammation in a rat model of acetic acid-induced ulcerative colitis.5
1.Vanhoof, R., Coignau, H., Stas, G., et al.Evaluation of the in vitro activity of nifuroxazide on enteropathogenic microorganisms: Determination of bacteriostatic and bactericidal concentrations and disk susceptibilityActa Clin. Belg.36(3)126-129(1981) 2.Yang, L., Rybtke, M.T., Jakobsen, T.H., et al.Computer-aided identification of recognized drugs as Pseudomonas aeruginosa quorum-sensing inhibitorsAntimicrob. Agents Chemother.53(6)2432-2443(2009) 3.Nelson, E.A., Walker, S.R., Kepich, A., et al.Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3Blood112(13)5095-5102(2008) 4.Yang, F., Hu, M., Lei, Q., et al.Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer modelCell Death Dis.6(3)e1701(2015) 5.El-Far, Y.M., Elsherbiny, N.M., El-Shafey, M., et al.The interplay of the inhibitory effect of nifuroxazide on NF-κB/STAT3 signaling attenuates acetic acid-induced ulcerative colitis in ratsEnviron. Toxicol. Pharmacol.79103433(2020)
| Cas No. | 1188487-83-3 | SDF | |
| 别名 | 硝呋齐特 d4 | ||
| Canonical SMILES | O=C(C1=C([2H])C([2H])=C(C([2H])=C1[2H])O)NN=CC2=CC=C([N+]([O-])=O)O2 | ||
| 分子式 | C12H5D4N3O5 | 分子量 | 279.2 |
| 溶解度 | DMF: soluble,DMSO: soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5817 mL | 17.9083 mL | 35.8166 mL |
| 5 mM | 0.7163 mL | 3.5817 mL | 7.1633 mL |
| 10 mM | 0.3582 mL | 1.7908 mL | 3.5817 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。